57614-63-8

Upstream product

• 88499-59-6 N₂-<(2,5-difluorophenyl)phenylmethylene>-N-methylhydrazinecarbothioamide 
• 85068-36-6 2,5-difluorobenzophenone 
• 6610-29-3 4-methylthiosemicarbazide 
• 540-36-3 para-difluorobenzene 
• 858629-06-8 5-fluoro-3-iodo-1H-indazole 
• 944904-49-8 tert-butyl 5-fluoro-3-iodo-1H-indazole-1-carboxylate 
• 98-80-6 phenylboronic acid 
• 98-88-4 benzoyl chloride 

Downstream Products

• 57614-64-9 5-fluoro-3-phenyl-1-piperidin-1-ylmethyl-1H-indazole 
• 1569280-41-6 C₁₉H₁₄FN₃O₂S 
• 1204771-72-1 C₁₇H₁₀FN₃O₂S 

Relevant academic research and scientific papers

Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP 1 receptor antagonists for treatment of overactive bladder by core structure replacement

We have designed a series of potent EP1 receptor antagonists. These antagonists are a series of 2-(1H-indazol-1-yl)-thiazoles in which the core structure was replaced with pyrazole-phenyl groups. In preliminary conscious rat cystometry experiments, two representative candidates, 2 and 22, increased bladder capacity. In particular, the increase using 22 was approximately 2-fold that of the baseline. More detailed profiling of this compound and further optimization of this series promises to provide a novel class of drug for treating overactive bladder (OAB).

ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans

The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure-activity relationships led to the discovery of ML212.

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

The Reaction of 4-Alkyl-3-thiosemicarbazides with β-Haloketones

The reactions of 4-alkyl-3-thiosemicarbazides with β-halophenones and o-halophenones gave 4,5-dihydro-N-alkyl-3-phenyl-1H-pyrazole-1-carbothioamides and 3-phenyl-1H-indazoles, respectively.